Cg Oncology, Inc.2025财年第三财季实现净利润-43.81百万美元，同比减少114.65%

市场透视2025-11-23

11月23日，Cg Oncology, Inc.（CGON.US）公布财报，公告显示公司2025财年第三财季净利润为-43.81百万美元，同比减少114.65%；其中营业收入为1.67百万美元，同比增加3783.72%，每股基本收益为-0.57美元。从资产负债表来看，Cg Oncology, Inc.（CGON.US）总负债42.27百万美元，其中短期债务912000.00美元，资产负债比为...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2585210113?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2025-11-23 00:01","share_image_url":"https://static.laohu8.com/9a95c1376e76363c1401fee7d3717173","id":"2585210113","market":"us","top_or_hot":-1,"title":"Cg Oncology, Inc.2025财年第三财季实现净利润-43.81百万美元，同比减少114.65%","media":"市场透视","content":"<div>\n<p>11月23日，Cg Oncology, Inc.（CGON.US）公布财报，公告显示公司2025财年第三财季净利润为-43.81百万美元，同比减少114.65%；其中营业收入为1.67百万美元，同比增加3783.72%，每股基本收益为-0.57美元。从资产负债表来看，Cg Oncology, Inc.（CGON.US）总负债42.27百万美元，其中短期债务912000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112300013897797d1a&s=b\">网页链接</a>\n\n</div>\n","source":"tencent","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Cg Oncology, Inc.2025财年第三财季实现净利润-43.81百万美元，同比减少114.65%</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCg Oncology, Inc.2025财年第三财季实现净利润-43.81百万美元，同比减少114.65%\n</h2>\n\n<h4 class=\"meta\">\n\n\n2025-11-23 00:01 北京时间&nbsp;&nbsp;&nbsp;<a href=http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112300013897797d1a&s=b><strong>市场透视</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>11月23日，Cg Oncology, Inc.（CGON.US）公布财报，公告显示公司2025财年第三财季净利润为-43.81百万美元，同比减少114.65%；其中营业收入为1.67百万美元，同比增加3783.72%，每股基本收益为-0.57美元。从资产负债表来看，Cg Oncology, Inc.（CGON.US）总负债42.27百万美元，其中短期债务912000.00美元，资产负债比为...</p>\n\n<a href=\"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112300013897797d1a&s=b\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4135","symbol_name":"资产管理与托管银行","start_time":0,"source_url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112300013897797d1a&s=b","article_id":"2585210113","we_media_id":null,"thumbnails":[],"rights":{"source":"tencent","url":"http://gu.qq.com/resources/shy/news/detail-v2/index.html#/?id=nesSN2025112300013897797d1a&s=b","rn_cache_url":null,"customStyle":"body{padding-top:10px;}#news_title{font-weight:bold;#titleStyle#;}#news_description span{font-size:12px;#descriptionStyle#;}.footer-note{#statement#}","selectors":".mod-LoadTzbdNews, body","filters":".relate-stock, .hot-list, .recom-box, .wx-sou","directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2585210113","pubTimestamp":1763827293,"columns":[],"sourceInfo":{"source_id":"tencent","name":"腾讯"},"weMediaInfo":null,"summary":"11月23日，Cg Oncology, Inc.公布财报，公告显示公司2025财年第三财季净利润为-43.81百万美元，同比减少114.65%；其中营业收入为1.67百万美元，同比增加3783.72%，每股基本收益为-0.57美元。从资产负债表来看，Cg Oncology, Inc.总负债42.27百万美元，其中短期债务912000.00美元，资产负债比为0.18，流动比率为0.23。机构评级：截至2025年11月23日，当前有12家机构对Cg Oncology, Inc.目标价做出预测，其中目标均价为71.50美元，其中最低目标价为55.00美元，最高目标价为100.00美元。","collect":0,"end_time":0,"defaultTopTitle":"qq.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4135":"资产管理与托管银行","BCG":"Binah Capital Group Inc"},"translate_title":"Cg Oncology, Inc. achieved net profit of-US $43.81 million in the third fiscal quarter of fiscal 2025, a year-on-year decrease of 114.65%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"BCG":1},"content_text":"11月23日，Cg Oncology, Inc.（CGON.US）公布财报，公告显示公司2025财年第三财季净利润为-43.81百万美元，同比减少114.65%；其中营业收入为1.67百万美元，同比增加3783.72%，每股基本收益为-0.57美元。从资产负债表来看，Cg Oncology, Inc.（CGON.US）总负债42.27百万美元，其中短期债务912000.00美元，资产负债比为0.18，流动比率为0.23。机构评级：截至2025年11月23日，当前有12家机构对Cg Oncology, Inc.目标价做出预测，其中目标均价为71.50美元，其中最低目标价为55.00美元，最高目标价为100.00美元。公司简介：CG Oncology Inc 是一家后期临床生物制药公司，专注于为患有膀胱癌的患者开发和商业化一种潜在的骨干膀胱保留治疗方法。该公司的候选药物 cretostimogene grenadenorepvec 是一种靶向溶瘤膀胱内给药的免疫治疗药物，目前正处于两项三期临床试验（一项高危卡介苗 (BCG) 无反应的非肌层浸润性膀胱癌 (NMIBC) 的试验和一项针对中危 NMIBC 的试验）以及一项针对高危 BCG 无反应性 NMIBC 的检查点抑制剂的二期临床研究。（以上内容为腾讯自选股基于公开消息，由程序或算法智能生成，仅作为用户看盘参考，不作为投资建议或交易依据。股市有风险，请谨慎决策。）","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-2","news_tag":"dataReport","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.40.0","shortVersion":"4.40.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2585210113","isCrawlerRequest":true}